Last month, BioXyTran Inc (OTCMKTS: BIXT) achieved a once-in-a-decade type event with their announcement of a perfect phase 2 clinical trial outcome with a 100% response...
Leronlimab is an immunomodulator that targets many diseases Multiple indications being pursued in parallel Proven safety profile, novel mechanism of action, & ease of application enables...